内分泌治疗相关的内分泌病——生物学、患病率及对乳腺癌管理的影响
Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer.
作者信息
Brown Kristy A, Andreopoulou Eleni, Andreopoulou Panagiota
机构信息
Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
出版信息
Oncol Hematol Rev. 2020 Spring;16(1):17-22. doi: 10.17925/ohr.2020.16.1.17. Epub 2020 Feb 16.
Abstract
Nearly 270,000 new breast cancer cases are predicted to be diagnosed in the USA in 2019 with more than 70% being estrogen receptor positive and treated using endocrine therapy. The suppression of estrogen biosynthesis or action via the use of ovarian suppression, aromatase inhibitors and selective estrogen receptor modulators/degraders, respectively, is effective in approximately 70% of women. The systemic inhibition of estrogen during breast cancer treatment is also associated with side effects due to the important endocrine functions of this steroid hormone, including its role in the maintenance of energy homeostasis and bone health. The current work will present perspectives of the impact of endocrine therapy from the point of view of breast medical oncology, endocrinology, and basic science.
摘要
预计2019年美国将有近27万例新发乳腺癌病例被诊断出来，其中70%以上为雌激素受体阳性，并采用内分泌疗法进行治疗。分别通过使用卵巢抑制、芳香化酶抑制剂和选择性雌激素受体调节剂/降解剂来抑制雌激素生物合成或作用，在大约70%的女性中是有效的。在乳腺癌治疗期间对雌激素进行全身抑制也会带来副作用，因为这种类固醇激素具有重要的内分泌功能，包括其在维持能量稳态和骨骼健康方面的作用。当前的工作将从乳腺医学肿瘤学、内分泌学和基础科学的角度阐述内分泌治疗的影响。
相似文献
1
Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer.内分泌治疗相关的内分泌病——生物学、患病率及对乳腺癌管理的影响
Oncol Hematol Rev. 2020 Spring;16(1):17-22. doi: 10.17925/ohr.2020.16.1.17. Epub 2020 Feb 16.
2
Molecular Action and Clinical Relevance of Aromatase Inhibitors.芳香化酶抑制剂的分子作用及临床相关性
Oncologist. 1998;3(2):129-130.
3
The effects of adjuvant endocrine therapy on bone health in women with breast cancer.辅助内分泌治疗对乳腺癌女性骨骼健康的影响。
J Endocrinol. 2019 Jun 1;241(3):R111-R124. doi: 10.1530/JOE-19-0077.
4
Selecting adjuvant endocrine therapy for breast cancer.选择乳腺癌的辅助内分泌治疗。
Oncology (Williston Park). 2004 Dec;18(14):1733-44, discussion 1744-5, 1748, 1751-4.
5
Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.绝经前和绝经后近期激素受体阳性乳腺癌患者的辅助内分泌治疗。
Clin Breast Cancer. 2014 Jun;14(3):147-53. doi: 10.1016/j.clbc.2013.12.010. Epub 2013 Dec 27.
6
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
7
Optimal adjuvant endocrine therapy for early breast cancer.早期乳腺癌的最佳辅助内分泌治疗
Womens Health (Lond). 2010 May;6(3):383-98. doi: 10.2217/whe.10.25.
8
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice.绝经后转移性乳腺癌患者的内分泌治疗：从文献和指南到临床实践。
Crit Rev Oncol Hematol. 2016 Apr;100:57-68. doi: 10.1016/j.critrevonc.2016.02.008. Epub 2016 Feb 18.
9
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.激素受体阳性乳腺癌女性的辅助内分泌治疗：美国临床肿瘤学会临床实践指南关于卵巢抑制的更新。
J Clin Oncol. 2016 May 10;34(14):1689-701. doi: 10.1200/JCO.2015.65.9573. Epub 2016 Feb 16.
10
Challenges in the endocrine management of breast cancer.乳腺癌内分泌治疗中的挑战。
Breast. 2003 Aug;12 Suppl 2:S2-19. doi: 10.1016/s0960-9776(03)80158-3.
引用本文的文献
1
Comprehensive genomic profiling reveals a unique genomic landscape in solid tumors in an Indian cancer cohort of 1000 patients: a single institutional experience.全面基因组分析揭示了印度1000例癌症患者队列实体瘤中的独特基因组格局：单机构经验。
Sci Rep. 2025 Apr 11;15(1):12455. doi: 10.1038/s41598-025-94762-z.
2
A promising target for breast cancer: B7-H3.乳腺癌有希望的治疗靶点：B7-H3。
BMC Cancer. 2024 Feb 7;24(1):182. doi: 10.1186/s12885-024-11933-3.
3
Editorial: Drug resistance in breast cancer - mechanisms and approaches to overcome chemoresistance.社论：乳腺癌中的耐药性——克服化疗耐药的机制与方法
Front Oncol. 2023 Jan 4;12:1080684. doi: 10.3389/fonc.2022.1080684. eCollection 2022.
4
PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.PARP抑制剂在乳腺癌和妇科癌症中的耐药性：耐药机制与联合治疗策略。
Front Pharmacol. 2022 Aug 25;13:967633. doi: 10.3389/fphar.2022.967633. eCollection 2022.
5
Metabolic pathways in obesity-related breast cancer.肥胖相关乳腺癌中的代谢途径。
Nat Rev Endocrinol. 2021 Jun;17(6):350-363. doi: 10.1038/s41574-021-00487-0. Epub 2021 Apr 29.
本文引用的文献
1
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.三期随机临床试验：双膦酸盐类药物作为乳腺癌辅助治疗：S0307。
J Natl Cancer Inst. 2020 Jul 1;112(7):698-707. doi: 10.1093/jnci/djz215.
2
A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy.一项比较二甲双胍与安慰剂对接受标准化疗的转移性乳腺癌女性无进展生存期影响的 II 期随机临床试验。
Breast. 2019 Dec;48:17-23. doi: 10.1016/j.breast.2019.08.003. Epub 2019 Aug 22.
3
Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women.双膦酸盐与原发性乳腺癌风险：一项纳入963,995名女性的更新的系统评价和荟萃分析
Clin Epidemiol. 2019 Jul 18;11:593-603. doi: 10.2147/CLEP.S194056. eCollection 2019.
4
The Association between Metformin Therapy and Lactic Acidosis.二甲双胍治疗与乳酸性酸中毒的关联。
Drug Saf. 2019 Dec;42(12):1449-1469. doi: 10.1007/s40264-019-00854-x.
5
Transactivation Function-1-Mediated Partial Agonist Activity of Selective Estrogen Receptor Modulator Requires Homo-Dimerization of the Estrogen Receptor α Ligand Binding Domain.雌激素受体 α 配体结合域同源二聚化是选择性雌激素受体调节剂的转录激活功能 1 介导的部分激动剂活性所必需的。
Int J Mol Sci. 2019 Jul 30;20(15):3718. doi: 10.3390/ijms20153718.
6
Selective oestrogen receptor degraders in breast cancer: a review and perspectives.选择性雌激素受体降解剂在乳腺癌中的应用：综述与展望。
Curr Opin Oncol. 2019 Sep;31(5):424-429. doi: 10.1097/CCO.0000000000000567.
7
Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.雌激素与乳腺癌：肥胖相关发展、生长和进展涉及的机制。
J Steroid Biochem Mol Biol. 2019 May;189:161-170. doi: 10.1016/j.jsbmb.2019.03.002. Epub 2019 Mar 6.
8
Association of Bone Metastasis With Early-Stage Breast Cancer in Women With and Without Precancer Osteoporosis According to Osteoporosis Therapy Status.根据骨质疏松症治疗状况，骨转移与有和无癌前骨质疏松症的女性早期乳腺癌的关联。
JAMA Netw Open. 2019 Mar 1;2(3):e190429. doi: 10.1001/jamanetworkopen.2019.0429.
9
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.辅助地舒单抗用于激素受体阳性乳腺癌（ABCSG-18）绝经后患者：一项随机、双盲、安慰剂对照、3 期临床试验的无病生存结果。
Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.
10
Abridged for Primary Care Providers.为初级保健提供者缩写。
Clin Diabetes. 2019 Jan;37(1):11-34. doi: 10.2337/cd18-0105.
Zotero 插件